Question · asked by 1 review
Gemcitabine vs BCG: Disease‐specific quality of life
- Population
- participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
- Intervention
- Gemcitabine
- Comparison
- BCG
- Outcome
- Disease‐specific quality of life
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Gemcitabine vs BCG Disease‐specific quality of life · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31… The review found no eligible studies for this question. Intravesical gemcitabine for non‐muscle invasive bladder cancer (2021) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Gemcitabine vs Normal saline · patients with non‐muscle invasive bladder cancer · 1 review
- Gemcitabine vs mitomycin · patients with non‐muscle invasive bladder cancer · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.